Compare Amgen, Inc. (AMGN) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Constellation Energy Corporation — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Constellation Energy Corporation trades at $279.38 (market cap $98.63B). The key difference: Amgen, Inc. is far larger — about 2.3× Constellation Energy Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | CEG | |
|---|---|---|
Market Cap | $224.14B | $98.63B |
Sector | Health | Energy |
52-Week High | $417.20 | $403.95 |
52-Week Low | $271.18 | $236.50 |
Enterprise Value | $267.45B | $122.63B |
Dividend Yield | 2.43% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
CEG trades at $278.68, up 3.05% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and Calpine integration. Revenue growth is robust, with 2026 projections at $31.3B, and profitability metrics like ROE of 15.26% highlight efficient capital use.
The stock offers upside to the consensus price target of $332.13, with 70% of analysts rating it Buy. Key risks include execution of growth initiatives and market volatility, but strong cash flow and strategic positioning in AI-driven power demand support a positive outlook for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
